GlassScriptPhysician profile
Sima Shukla
NPI 1245330182
$2,477.66
in general payments reported to CMS, 2019-2025
13 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $207 · 2021: $135 · 2022: $856 · 2023: $193 · 2024: $397 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $860.59 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $666.95 | 2019-2023 | Xarelto |
| Abbvie INC. | $188.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.39 | 2022 | |
| Merck Sharp & Dohme LLC | $164.75 | 2022-2025 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $151.72 | 2019-2024 | |
| Amarin Pharma, INC. | $113.97 | 2019-2021 | |
| Qorumpartners | $36.02 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $35.48 | 2024 | Opsumit |
| Eisai INC. | $29.37 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.74 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.38 | 2019 | |
| Amgen INC. | $16.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sima Shukla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.